A director at Monash Ivf Group Ltd maiden bought 77,000 shares at 1.211AUD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
MONASH IVF GROUP (AU), a company active in the Medical Equipment industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 4 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date January 11, 2022, the closing pric...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Previously highlighted as a value name in our analysis released March 25, 2020, VF Corp. (VFC) has unveiled its plan for reopening stores across the Middle East, Europe and the United States as pandemic restrictions begin to ease. The earnings might have missed expectations on Friday (May 15), but digital sales and the ongoing reopening plan are clear positives moving forward, and the stock provides a value-oriented entry level at the same price as we recommended two months ago. The Edge View.....
To inform our analysis into finding the next value ideas in this current market environment, we started by examining the sectors that outperformed the S&P 500 Index following the 2008 financial crisis (recovery started on March 2, 2009). The data shows six sectors (out of the total 11) that have consistently outperformed the S&P 500 Index in the five years after the recovery. We have narrowed down to three names (one European and two US) that are worth buying at current levels. The Edge View......
We plan to cease coverage of no-moat Monash IVF in early November 2018. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Monash is a small, high-risk, no-moat company. The firm’s near-term earnings growth looks to remain muted, with management guiding to a 15% decline in first-half 2019 earnings compared with first-half 2018, given the inclusion of one quarter o...
We plan to cease coverage of no-moat Monash IVF in early November 2018. We provide broad coverage of more than 1,500 companies across more than 90 industry groups globally and adjust our coverage as necessary based on client demand and investor interest. Monash is a small, high-risk, no-moat company. The firm’s near-term earnings growth looks to remain muted, with management guiding to a 15% decline in first-half 2019 earnings compared with first-half 2018, given the inclusion of one quarter o...
No-moat Monash IVF's full-year fiscal 2018 results were mixed and highlighted the negative impact of lower volumes on EBITDA margins given lower operating leverage. After adjusting for one-off costs of AUD 1.2 million, largely related to legal fees and recruitment of key personnel, reported net profit after tax, or NPAT, of AUD 21.4 million, down 27.9% year on year, was slightly below our forecast of AUD 23.2 million. Although average revenue per blended fresh IVF cycle was albeit 5% higher th...
No-moat Monash IVF's full-year fiscal 2018 results were mixed and highlighted the negative impact of lower volumes on EBITDA margins given lower operating leverage. After adjusting for one-off costs of AUD 1.2 million, largely related to legal fees and recruitment of key personnel, reported net profit after tax, or NPAT, of AUD 21.4 million, down 27.9% year on year, was slightly below our forecast of AUD 23.2 million. Although average revenue per blended fresh IVF cycle was albeit 5% higher th...
No-moat Monash IVF's full-year fiscal 2018 results were mixed and highlighted the negative impact of lower volumes on EBITDA margins given lower operating leverage. After adjusting for one-off costs of AUD 1.2 million, largely related to legal fees and recruitment of key personnel, reported net profit after tax, or NPAT, of AUD 21.4 million, down 27.9% year on year, was slightly below our forecast of AUD 23.2 million. Although average revenue per blended fresh IVF cycle was albeit 5% higher th...
We maintain our AUD 1.60 fair value estimate for no-moat-rated Monash IVF Group following the most recent release of Medicare IVF fresh and frozen volume data (Medicare items 13200, 13201, 13202, 13218) for May 2018. Total fresh and frozen cycle volumes at a national level, on a combined 12-month rolling basis, increased by 2.8% and thus came in broadly in line with our volume growth assumptions for the industry. Despite the near-term challenges in Victoria, which we see continuing into the sec...
Monash IVF Group is a major provider of in vitro fertilisation, or IVF, services with 23% of the national market. It's one of two pure plays listed on the Australian Securities Exchange. Notwithstanding significant market share in Victoria and an expanding presence in New South Wales, Monash is underrepresented in higher-growth markets on Australia's east coast. The IVF market is characterised by a relatively small pool of fertility specialists nationwide, exposing all players to key personnel r...
We maintain our AUD 1.60 fair value estimate for no-moat-rated Monash IVF Group following the most recent release of Medicare IVF fresh and frozen volume data (Medicare items 13200, 13201, 13202, 13218) for May 2018. Total fresh and frozen cycle volumes at a national level, on a combined 12-month rolling basis, increased by 2.8% and thus came in broadly in line with our volume growth assumptions for the industry. Despite the near-term challenges in Victoria, which we see continuing into the se...
No-moat Monash IVF Group delivered first-half fiscal 2018 results in line with guidance provided at the annual general meeting, with net profit after tax, or NPAT, of AUD 12.1 million on group revenue of AUD 77 million, down 20.9% and 2.2%, respectively, on the prior comparable period. However, management surprised by issuing maiden guidance of a 25% NPAT decline for the full year. Notwithstanding state-specific issues across four key markets, including increased low-cost competition in Queensla...
We reduce our fair value estimate for no-moat-rated Monash IVF Group to AUD 1.60 from AUD 1.80, following guidance provided at the annual general meeting that flagged first-half 2018 net profit after tax of around AUD 12 million, or 20% lower than the previous corresponding period. This was due to a combination of one-off expenses related to legal costs and CEO recruitment, amounting to around AUD 600,000 pretax, and a 6.6% decline on the prior corresponding period in Monash fresh IVF volumes fo...
We reduce our fair value estimate for no-moat-rated Monash IVF Group to AUD 1.60 from AUD 1.80, following guidance provided at the annual general meeting that flagged first-half 2018 net profit after tax of around AUD 12 million, or 20% lower than the previous corresponding period. This was due to a combination of one-off expenses related to legal costs and CEO recruitment, amounting to around AUD 600,000 pretax, and a 6.6% decline on the prior corresponding period in Monash fresh IVF volumes fo...
We are reducing our fair value estimate to AUD 1.80 per share from AUD 2.00 for no-moat-rated Monash IVF group following a slightly weaker-than-expected result, combined with a subdued fiscal 2018 outlook that implies net profit after tax will remain effectively flat. NPAT for fiscal 2017 was AUD 29.6 million on group revenue of AUD 155.2 million, up 2.9% and down 0.9%, respectively, on the prior corresponding period. This compares with our forecast NPAT of AUD 31.3 million. However, EBITDA mar...
We are reducing our fair value estimate to AUD 1.80 per share from AUD 2.00 for no-moat-rated Monash IVF group following a slightly weaker-than-expected result, combined with a subdued fiscal 2018 outlook that implies net profit after tax will remain effectively flat. NPAT for fiscal 2017 was AUD 29.6 million on group revenue of AUD 155.2 million, up 2.9% and down 0.9%, respectively, on the prior corresponding period. This compares with our forecast NPAT of AUD 31.3 million. However, EBITDA mar...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.